[go: up one dir, main page]

AR104806A1 - Nanopartículas para uso como vacuna terapéutica - Google Patents

Nanopartículas para uso como vacuna terapéutica

Info

Publication number
AR104806A1
AR104806A1 ARP160101554A ARP160101554A AR104806A1 AR 104806 A1 AR104806 A1 AR 104806A1 AR P160101554 A ARP160101554 A AR P160101554A AR P160101554 A ARP160101554 A AR P160101554A AR 104806 A1 AR104806 A1 AR 104806A1
Authority
AR
Argentina
Prior art keywords
cancer
nanoparticles
subject
nanoparticle
vaccine composition
Prior art date
Application number
ARP160101554A
Other languages
English (en)
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of AR104806A1 publication Critical patent/AR104806A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una composición de vacuna que comprende una nanopartícula y/o agregado de nanopartículas para uso en el tratamiento de cáncer en un sujeto que padece un cáncer metastásico o un cáncer de líquido, en tanto el tratamiento comprende exponer al sujeto a una radioterapia fraccionada que comprende al menos un paso de irradiación donde la dosis de radiaciones ionizantes oscila entre 1.8 y 20 Gray (Gy), y cada nanopartícula comprende un material que posee una densidad de por lo menos 7 g/cm³ y un número atómico (Z) de por lo menos 25 y cada nanopartícula o agregado de nanopartículas está cubierto por un recubrimiento biocompatible que permite la estabilidad de la nanopartícula entre un pH de 6.5 y 7.5 en un fluido fisiológico. Reivindicación 5: La composición de vacuna para uso de acuerdo a cualquiera de las reivindicaciones 1 a 3 en la cual, cuando el cáncer es un cáncer metastásico, el por lo menos único paso de irradiación se aplica ex vivo a una muestra de cáncer del sujeto que comprende las nanopartículas o agregados de nanopartículas, en tanto las células de cáncer letalmente irradiadas ex vivo y por lo menos parte del sobrenadante celular asociado de la muestra de cáncer son por lo menos parcialmente readministrados al sujeto antes de cualquier otro tratamiento en vivo subsecuente opcional del cáncer en dicho sujeto. Reivindicación 17: La composición de vacuna para uso de acuerdo a la reivindicación 15 o el kit de acuerdo a la reivindicación 16, donde el por lo menos único agente inmunoterapéutico se selecciona entre un anticuerpo monoclonal, una citoquina, y una combinación de los mismos.
ARP160101554A 2015-05-28 2016-05-27 Nanopartículas para uso como vacuna terapéutica AR104806A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15305810 2015-05-28

Publications (1)

Publication Number Publication Date
AR104806A1 true AR104806A1 (es) 2017-08-16

Family

ID=53298299

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101554A AR104806A1 (es) 2015-05-28 2016-05-27 Nanopartículas para uso como vacuna terapéutica

Country Status (18)

Country Link
US (2) US11096962B2 (es)
EP (1) EP3302419B1 (es)
JP (2) JP2018516256A (es)
KR (1) KR102727195B1 (es)
CN (2) CN118286421A (es)
AR (1) AR104806A1 (es)
AU (2) AU2016269146B2 (es)
BR (1) BR112017025553A2 (es)
EA (1) EA201792560A1 (es)
HK (1) HK1246160A1 (es)
IL (1) IL255853B (es)
MA (1) MA43100A (es)
MX (2) MX2017015424A (es)
NZ (1) NZ738527A (es)
TW (1) TWI873079B (es)
UA (1) UA124572C2 (es)
WO (1) WO2016189125A1 (es)
ZA (1) ZA201708686B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
CN109010828B (zh) * 2018-10-12 2020-10-20 中国科学院高能物理研究所 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途
EP3866832B1 (en) 2018-10-19 2024-12-11 University of Rochester Immunomodulatory cytokines in combination with radiation treatment for unresectable pancreatic cancer
MX2023005314A (es) * 2020-11-05 2023-05-25 Nanobiotix Composiciones de nanoparticulas para tratamiento de cancer.
EP4633676A1 (en) 2022-12-12 2025-10-22 Nanobiotix Novel metal oxide nanoparticles and compositions thereof for use as radioenhancers or for visualizing biological tissue
CN116370625B (zh) * 2023-03-14 2024-10-11 浙江大学 一种哑铃状的金-氧化铈纳米材料的制备方法及其产品和应用

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US4672040A (en) 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6099457A (en) 1990-08-13 2000-08-08 Endotech, Inc. Endocurietherapy
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
CA2137145A1 (en) 1992-06-08 1993-12-23 Mark S. Chagnon Preparation of controlled size inorganic particles for use in separations, as magnetic molecular switches, and as inorganic liposomes for medical applications
EP0654973A4 (en) 1992-07-21 1995-08-09 Gen Hospital Corp ARRANGEMENT FOR DELIVERING MEDICINES TO THE LYMPHIC TISSUE.
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
ES2188652T3 (es) 1994-02-28 2003-07-01 Nanopharm Ag Sistema de direccionado de farmacos, metodos de fabricacion y uso del mismo.
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
ATE233546T1 (de) 1997-03-07 2003-03-15 Max Delbrueck Centrum Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
US6161034A (en) 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
WO2000006244A2 (en) 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
US6514481B1 (en) 1999-11-22 2003-02-04 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
AU2001236798B2 (en) 2000-02-08 2004-11-04 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
JP2003532898A (ja) 2000-05-05 2003-11-05 バイエル アクチェンゲゼルシャフト 生体標識としてのドープ処理されたナノ粒子
DE60137953D1 (de) 2000-10-06 2009-04-23 Life Technologies Corp Zellen mit spektraler signatur sowie verfahren zu ihrer herstellung und nutzung
IL154758A0 (en) 2000-11-20 2003-10-31 Oncolytics Biotech Inc Method for optimally delivering virus to a solid tumor mass
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
US6756063B2 (en) 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
DE10154016B4 (de) 2001-10-26 2004-02-12 Berlin Heart Ag Magnetflüssigkeit und Verfahren zur ihrer Herstellung
AU2002351240A1 (en) 2002-03-08 2003-09-22 James Hainfeld Gold nanoparticles used for x-rays imaging
US20030191458A1 (en) 2002-04-03 2003-10-09 Cornelius Diamond Light-activated drug delivery method and device
US7769423B2 (en) 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
US20030125283A1 (en) 2002-09-16 2003-07-03 Gatenby Robert A. Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents
JP4800922B2 (ja) 2003-01-24 2011-10-26 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 光線力学療法用の治療薬を封入するためのセラミックベースナノ粒子及びその使用方法
US7235228B2 (en) 2003-04-15 2007-06-26 The United States Of America As Represented By The Secretary Of The Navy Fluorescent-magnetic nanoparticles with core-shell structure
US20050084869A1 (en) 2003-10-20 2005-04-21 Sung Hyun Kim Novel composition and methods for the diagnosis of lung cancer
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
EP1687034A1 (en) 2003-11-17 2006-08-09 Philips Intellectual Property & Standards GmbH Contrast agent for medical imaging techniques and usage thereof
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
EP1720521A4 (en) 2004-02-10 2008-11-05 Barnes Jewish Hospital IMPROVED EFFICIENCY AND SAFETY OF TARGETED MEANS WITH DECOY SYSTEMS
JP4895151B2 (ja) 2004-02-27 2012-03-14 日立金属株式会社 鉄系ナノサイズ粒子およびその製造方法
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20050260137A1 (en) 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging
US20070031337A1 (en) 2004-06-22 2007-02-08 Reinhard Schulte Nanoparticle enhanced proton computed tomography and proton therapy
GB2415374A (en) 2004-06-25 2005-12-28 Leuven K U Res & Dev Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles
WO2006037081A2 (en) 2004-09-28 2006-04-06 The Regents Of The University Of California Nanoparticle radiosensitizers
FR2877571B1 (fr) 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
EP1810688A1 (en) 2004-11-10 2007-07-25 Konica Minolta Medical & Graphic, Inc. Pharmaceutical preparation containing coated magnetic particles and method for production thereof, and diagnosis therapy system
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
FR2884149B1 (fr) 2005-04-12 2007-06-08 Henri Mehier Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal
US20070092927A1 (en) 2005-06-13 2007-04-26 University Of Dayton Photocatalytic particles with directed and controlled redox activity
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
EP1942950A2 (en) 2005-11-01 2008-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
US20070098641A1 (en) 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
KR100745744B1 (ko) 2005-11-11 2007-08-02 삼성전기주식회사 나노 입자 코팅 방법
WO2007122956A1 (ja) 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
WO2007116954A2 (en) 2006-03-30 2007-10-18 Fujifilm Corporation Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
EP1852107A1 (en) 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
EP2019665B1 (en) 2006-05-04 2018-09-19 Reformpharm Pty Ltd Drug release from nanoparticle-coated capsules
JP2009544584A (ja) 2006-07-10 2009-12-17 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 治療及び画像化を目的とするコア・シェル構造ナノ粒子
DE102006041495A1 (de) 2006-08-29 2008-03-20 Friedrich-Schiller-Universität Jena Substanzgemisch zur lokalen Deposition von Magnetpartikeln in einem Medium, insbesondere in tumorbefallenem organischem Gewebe, sowie Applikationskit zur Verabreichung
NO329127B1 (no) 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
NO20064315L (no) 2006-09-22 2008-03-24 Epitarget As T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav
IL181126A0 (en) 2006-11-01 2007-07-04 S B Biotechnologies Ltd Preparation of gold-containing nano-liposome particles and their use in medical therapy
EP1920784A1 (en) 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Radiation sensitizers in ionizing radiation therapy and imaging
US20090004258A1 (en) 2007-06-27 2009-01-01 National Health Research Institutes Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field
CN101795671A (zh) 2007-08-21 2010-08-04 阿尔扎公司 用于体内施用硼酸化合物的脂质体组合物
JP2009067613A (ja) 2007-09-11 2009-04-02 Fujifilm Corp コア−シェル型金属酸化物微粒子及びその製造方法
US20120176016A1 (en) 2007-09-28 2012-07-12 General Electric Company Core-shell particulates, articles, and method of making
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2067485A1 (en) 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Drug carrier providing MRI contrast enhancement
US20100272639A1 (en) 2007-12-21 2010-10-28 John Robert Dutcher Polysaccharide nanoparticles
DE102008003615A1 (de) 2008-01-09 2009-07-16 Magforce Nanotechnologies Ag Magnetische Transducer
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
EP2280601A4 (en) 2008-02-21 2012-08-29 Sequoia Pharmaceuticals Inc AMINOACIDAL INHIBITORS OF CYTOCHROME P450
DE102008000852A1 (de) 2008-03-27 2009-10-01 Bosch Mahle Turbo Systems Gmbh & Co. Kg Abgasturbolader für ein Kraftfahrzeug
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) * 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
US8395131B2 (en) 2009-06-20 2013-03-12 Xiaodong Wu Method for three dimensional (3D) lattice radiotherapy
EP2275137A1 (en) 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
EP2305310A1 (en) 2009-09-25 2011-04-06 Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE Gold -coated magnetic glyconanoparticles functionalised with proteins for use as diagnostic and therapeutic agents
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
EP3583960A1 (en) 2009-12-15 2019-12-25 Incept, LLC Implants and biodegradable fiducial markers
CN102781472B (zh) 2010-02-17 2014-07-02 国立大学法人神户大学 放射线治疗剂
LT2552438T (lt) 2010-03-26 2016-09-26 Abraxis Bioscience, Llc Hepatoceliulinės karcinomos gydymo būdai
CN105931697B (zh) 2010-04-23 2018-04-06 皮瑟莱根特科技有限责任公司 纳米晶体的合成、盖帽和分散
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
US20130177523A1 (en) 2010-07-13 2013-07-11 University Of Utah Research Foundation Gold particles and methods of making and using the same in cancer treatment
US9095558B2 (en) 2010-10-08 2015-08-04 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
US9956175B2 (en) 2011-01-31 2018-05-01 Nanobiotix Nanoparticles delivery systems, preparation and uses thereof
JP2014503575A (ja) 2011-01-31 2014-02-13 ナノビオティックス 超常磁性のナノ粒子を用いて、興味対象生成物のリポソームからの放出をモニターする方法
WO2012156532A1 (en) * 2011-05-19 2012-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-her3 antibodies and uses thereof
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
EP2782603A1 (en) 2011-11-25 2014-10-01 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
HK1203353A1 (en) 2011-12-16 2015-10-30 Nanobiotix Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
US8859499B2 (en) 2012-03-20 2014-10-14 Albert Einstein College Of Medicine Of Yeshiva University Method of enhancing efficacy of blood transfusions
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140213765A1 (en) 2013-01-25 2014-07-31 I-Liang Lee Albumin tissue scaffold
EP2948179B1 (en) 2013-01-25 2019-06-19 Nanobiotix Compositions comprising nanoparticles of hafnium (iv) oxide or rhenium (iv) oxide in combination with ionizing radiations for treating cancer
US20140219926A1 (en) 2013-02-01 2014-08-07 The Trustees Of Dartmouth College Biodegradable Iron Oxide Nanoparticle Gel for Tumor Bed Therapy
JP6387400B2 (ja) 2013-05-30 2018-09-05 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 医薬組成物、その製造および使用
HK1222562A1 (zh) 2013-06-20 2017-07-07 Nanobiotix 用於医学诊断的组合物及方法
SI3010552T1 (sl) 2013-06-20 2019-08-30 Nanobiotix Sestavki za uporabo v onkologiji
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
CA2968473A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
JP6835733B2 (ja) 2014-11-25 2021-02-24 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 医薬組成物、その調製法及び使用
PT3229843T (pt) 2014-11-25 2020-03-06 Curadigm Sas Composição farmacêutica, a sua preparação e as suas utilizações
AR102782A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composición farmacéutica, su preparación y sus usos
LT3229776T (lt) 2014-11-25 2023-08-25 Curadigm Sas Farmacinė kompozicija, kurioje derinamos mažiausiai dvi skirtingos nanodalelės ir farmacinis mišinys, jos paruošimas ir vartojimas

Also Published As

Publication number Publication date
CN118286421A (zh) 2024-07-05
AU2021202582B2 (en) 2022-12-15
NZ738527A (en) 2022-07-01
EP3302419A1 (en) 2018-04-11
MA43100A (fr) 2018-09-05
JP2023082080A (ja) 2023-06-13
BR112017025553A2 (pt) 2018-08-07
ZA201708686B (en) 2025-03-26
UA124572C2 (uk) 2021-10-13
AU2016269146A1 (en) 2018-01-18
US20180147237A1 (en) 2018-05-31
KR20180012823A (ko) 2018-02-06
TW201705977A (zh) 2017-02-16
EA201792560A1 (ru) 2018-06-29
AU2021202582A1 (en) 2021-05-27
US20210353670A1 (en) 2021-11-18
NZ776598A (en) 2024-10-25
EP3302419B1 (en) 2026-01-21
TW202417036A (zh) 2024-05-01
HK1246160A1 (zh) 2018-09-07
IL255853A (en) 2018-01-31
US11096962B2 (en) 2021-08-24
CA2987331A1 (en) 2016-12-01
CN107708668A (zh) 2018-02-16
MX2023007706A (es) 2023-07-10
JP2018516256A (ja) 2018-06-21
IL255853B (en) 2020-08-31
AU2016269146B2 (en) 2021-01-28
TWI873079B (zh) 2025-02-21
MX2017015424A (es) 2018-03-01
KR102727195B1 (ko) 2024-11-06
JP7570134B2 (ja) 2024-10-21
WO2016189125A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
AR104806A1 (es) Nanopartículas para uso como vacuna terapéutica
UY38389A (es) Dispositivos implantables para terapia celular y métodos relacionados
DOP2022000128A (es) Compuestos y métodos para la degradación dirigida del receptor de andrógenos
CL2022000922A1 (es) Aminas bicíclicas como inhibidores de la cdk2.
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CO2020001960A2 (es) Formulaciones de anticuerpos anti-c5 de alta concentración
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
BR112019001055A2 (pt) anticorpos anti-gprc5d, moléculas de ligação a antígeno biespecíficas que se ligam a gprc5d e a cd3, e usos dos mesmos
CO2018014010A2 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
BR112012022802A2 (pt) uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
MY180365A (en) Markers of tumor cell response to anti-cancer therapy
EA201171195A8 (ru) Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
AR075982A1 (es) Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
UA116007C2 (uk) Композиції неорганічних наночастинок у комбінації з іонізуючим випромінюванням для лікування раку
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
CO2019003865A2 (es) Proteína terapéutica
BR112015031984A2 (pt) gel biocompatível compreendendo nanopartículas e/ou agregados de nanopartículas; e kit compreendendo um gel biocompatível
EA202192964A1 (ru) Комбинированная терапия
CO2021005872A2 (es) Composiciones y métodos para la estimulación ovárica controlada
McMahon et al. Comment on ‘Implications on clinical scenario of gold nanoparticle radiosensitization in regards to photon energy, nanoparticle size, concentration and location’
HRP20190848T1 (hr) Pripravci namijenjeni upotrebi u onkologiji
Omelchenko et al. Manifestation of synergism under simultaneous action of hyperthermia and antitumor drugs on yeast cells

Legal Events

Date Code Title Description
FB Suspension of granting procedure